Sugi Predict

Sugi Predict / Compounds / SCHEMBL1123027

SCHEMBL1123027

SCHEMBL1123027

CC(C)CC(N)CCC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 2/20 0.60
▸ GABRD O14764 2/20 0.60
▸ GABRA1 P14867 2/20 0.60
▸ GABRB1 P18505 2/20 0.60
▸ GABRG2 P18507 2/20 0.60
▸ GABRB3 P28472 2/20 0.60
▸ GABRA5 P31644 2/20 0.60
▸ GABRA3 P34903 2/20 0.60
▸ GABRA2 P47869 2/20 0.60
▸ GABRB2 P47870 2/20 0.60
▸ GABRA4 P48169 2/20 0.60
▸ GABRE P78334 2/20 0.60
▸ GABRA6 Q16445 2/20 0.60
▸ GABRG1 Q8N1C3 2/20 0.60
▸ GABRG3 Q99928 2/20 0.60
▸ GABRQ Q9UN88 2/20 0.60
▸ ENPEP Q07075 5/20 0.56
▸ ANPEP P15144 3/20 0.56
▸ CYP1A2 P05177 2/20 0.48
▸ SLC7A5 Q01650 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288675 1.00 GABRP (0.60) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL18822642 1.00 GABRP (0.60) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL9129209 0.98 GABRP (0.58) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8514064 0.84 GABRP (0.58) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL10098467 0.82 PMP22 (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL16103400 0.82 PMP22 (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL18822349 0.82 PMP22 (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL298866 0.82 GABRP (0.60) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL298867 0.82 GABRP (0.60) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5998671 0.81 GABRP (0.54) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 — — EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 — — US disclosed
US-11981704-B2 Decarboxylative conjugate additions and applications thereof THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2024-05-14 — — US disclosed
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2024-04-18 — — US disclosed
US-20230303647-A1 CYCLIC CHEMERIN-9 DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2023-09-28 — — US disclosed
CN-116390742-A Cyclic chemokine-9 derivatives 拜耳公司 2023-07-04 — — CN disclosed
EP-4196143-A1 CYCLIC CHEMERIN-9 DERIVATIVES Bayer Aktiengesellschaft (DE) 2023-06-21 — — EP disclosed
US-11667675-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2023-06-06 — — US disclosed
US-11576879-B2 Multidrug pain management package ALGIA PHARMA, LLC (US) 2023-02-14 — — US disclosed
CN-114585637-A MASP inhibiting compounds and uses thereof 拜耳公司 2022-06-03 — — CN disclosed
EP-1874800-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS Karyon-CTT Ltd (FI) 2008-01-09 — — EP disclosed
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 — — US disclosed
CN-1310872-C Mono- and disubstituted 3-propyl gamma-aminobutyric acids WARNER LAMBERT CO (US) 2007-04-18 — — CN disclosed
WO-2006114478-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2006-11-02 — — WO disclosed
CN-1660779-A Mono- and disubstituted 3-propyl gamma-aminobutyric acids WARNER LAMBERT CO (US) 2005-08-31 — — CN disclosed
US-20050113293-A1 Medical uses of intercellular communication facilitating compounds ZEALAND PHARMA A/S 2005-05-26 — — US disclosed
CN-1196671-C Mono-and disubstituted 3-propyl-gamma-aminobutyric acids WARNER LAMBERT CO (US) 2005-04-13 — — CN disclosed
EP-1370276-A2 MEDICAL USES OF INTERCELLULAR COMMUNICATION FACILITATING COMPOUNDS Zealand Pharma A/S (DK) 2003-12-17 — — EP disclosed
WO-2002077017-A2 MEDICAL USES OF INTERCELLULAR COMMUNICATION FACILITATING COMPOUNDS ZEALAND PHARMA A/S (DK) 2002-10-03 — — WO disclosed
CN-1355784-A Mono-and disubstituted 3-propyl-gamma-aminobutyric acids WARNER LAMBERT CO (US) 2002-06-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503491-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 GABRP 1494/4885GABRD 3949/4885GABRA1 3890/4885
US-20050113293-A1 Medical uses of intercellular communication facilitating compounds GJB2, GJA1, TNNI3 GABRP 1415/4885GABRD 1393/4885GABRA1 2652/4885
US-20230303647-A1 CYCLIC CHEMERIN-9 DERIVATIVES CMKLR1, CMKLR2, CCL2 GABRP 2213/4885GABRD 2644/4885GABRA1 2828/4885
US-11667675-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 GABRP 1494/4885GABRD 3949/4885GABRA1 3890/4885
US-11981704-B2 Decarboxylative conjugate additions and applications thereof PTMS, DNPEP, QPCT GABRP 538/4885GABRD 267/4885GABRA1 980/4885
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 GABRP 2478/4885GABRD 3039/4885GABRA1 4391/4885
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF MASP2, SERPINB1, SPINT2 GABRP 1494/4885GABRD 3949/4885GABRA1 3890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.